Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Femasys Inc.
ATLANTA, July 8, 2014 /PRNewswire/ -- Femasys Inc., an emerging medical device developer of women's healthcare solutions, announced today that it has entered into a nationwide distribution agreement with McKesson Medical-Surgical to sell and distribute Femasys' FEMCERV® Endocervical Sampler. FEMCERV collects a tissue sample of a woman's endocervical canal for histological analysis when cervical cancer is suspected.
Under terms of the agreement, McKesson Medical-Surgical will sell and distribute the FEMCERV device nationwide through its sales force. Kathy Lee-Sepsick, President & CEO of Femasys commented, "We are thrilled to create an alliance with McKesson Medical-Surgical in bringing FEMCERV to the market as a novel new advancement in tissue sample collection for cervical cancer diagnosis. With McKesson Medical-Surgical's extensive market presence, physicians will gain access across the country to this much needed technology that has been designed with the woman and her anatomy in mind. Clinical data has demonstrated that physicians find FEMCERV easy to insert and well tolerated by almost all patients, who experienced mild or no discomfort."
"We're pleased to offer Femasys' FEMCERV product to our customers," said Joan Eliasek, Senior Vice President, Supplier Management, McKesson Medical-Surgical. "As a company, we are in business for one reason: better health. And fighting cancer is a major aspect of better health in our country. We are glad to offer products to our customers that help them deliver better care for their patients."
FEMCERV is intended for women who have received an abnormal pap smear result or have other factors that require a sampling of her cervical canal (i.e. cervical lesions extending into the canal or when there is undiagnosed uterine bleeding). The device minimizes the risk of incomplete sampling and optimizes diagnostic acuity by collecting a complete 360 degree sample, while protecting the sample from contamination. Endocervical curettage has the potential to decrease the number of unnecessary surgical treatments and to play a role in reducing the number of undiagnosed cases of cervical cancer. For additional information on the FEMCERV device, please visit www.femcerv.com.
McKesson Medical-Surgical's parent, McKesson Corporation, currently ranked 14th on the FORTUNE 500 list, is a healthcare services and information technology company dedicated to making the business of healthcare run better. McKesson Medical-Surgical works with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, please visit http://www.mckesson.com.
About Femasys Inc.
Femasys Inc., based in Atlanta, GA, is a privately held corporation committed to advancing women's healthcare worldwide by expanding options for women with innovative medical devices and next generation advancements providing significant clinical impact.
For additional information on Femasys and our other products, please visit www.femasys.com.
Business Development Contact:
Steven Damon, 770.598.6446, firstname.lastname@example.org
Jerry Fink, 770.500.3910, email@example.com
©2012 PR Newswire. All Rights Reserved.